Arvinas to Participate in Upcoming Investor Conferences
2024年3月4日 - 9:00PM
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology
company creating a new class of drugs based on targeted protein
degradation, today announced that management will participate in
three upcoming investor conferences:
- Leerink Partners Global Biopharma Conference
on Tuesday, March 12.
- Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D.,
interim chief financial officer, will participate in a fireside
chat. A live audio webcast of the presentation will be available
here and on the Events + Presentations section of the Company’s
website.
- Jefferies Biotech on the Bay Summit on
Wednesday, March 13.
- Ron Peck, M.D., chief medical officer, and Randy Teel, Ph.D.,
interim chief financial officer, will participate in investor 1x1
meetings.
- UBS Virtual CNS Day 2024 on Monday, March 18.
- Ian Taylor, Ph.D., chief scientific officer, and Angela Cacace,
Ph.D., senior vice president of neuroscience and platform biology,
will participate in a fireside chat. A live audio webcast of the
presentation will be available here and on the Events +
Presentations section of the Company’s website.
About ArvinasArvinas is a clinical-stage
biotechnology company dedicated to improving the lives of patients
suffering from debilitating and life-threatening diseases through
the discovery, development, and commercialization of therapies that
degrade disease-causing proteins. Arvinas uses its proprietary
PROTAC® Discovery Engine platform to engineer proteolysis targeting
chimeras, or PROTAC® targeted protein degraders, that are designed
to harness the body’s own natural protein disposal system to
selectively and efficiently degrade and remove disease-causing
proteins. In addition to its robust preclinical pipeline of PROTAC
protein degraders against validated and “undruggable” targets, the
company has four investigational clinical-stage programs:
vepdegestrant (ARV-471) for the treatment of patients with locally
advanced or metastatic ER+/HER2- breast cancer; ARV-766 and
bavdegalutamide for the treatment of men with metastatic
castration-resistant prostate cancer; and ARV-102 for the treatment
of patients with neurodegenerative disorders. For more information,
visit www.arvinas.com.
Contacts
Investors:Jeff Boyle+1 (347)
247-5089Jeff.Boyle@arvinas.com
Media:Kathleen Murphy+1 (760)
622-3771Kathleen.Murphy@arvinas.com
Arvinas (NASDAQ:ARVN)
過去 株価チャート
から 4 2024 まで 5 2024
Arvinas (NASDAQ:ARVN)
過去 株価チャート
から 5 2023 まで 5 2024